879-93-6

Basic information

• Product Name: 4-BroMo-3-nitrobenzaMide
• Synonyms: 4-BroMo-3-nitrobenzaMide
• CAS NO: 879-93-6
• Molecular Formula: C₇H₅BrN₂O₃
• Molecular Weight: 245
• Mol File: 879-93-6.mol

Chemical Properties

• Boiling Point: 297.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.799±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.58±0.50(Predicted)
• CAS DataBase Reference: 4-BroMo-3-nitrobenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-3-nitrobenzaMide(879-93-6)
• EPA Substance Registry System: 4-BroMo-3-nitrobenzaMide(879-93-6)

Safety Data

• Hazardous Substances Data: 879-93-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3-nitrobenzamide is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure with a bromine atom and a nitro group attached to the benzene ring allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
4-Bromo-3-nitrobenzamide is used as a precursor in the production of agrochemicals. Its chemical properties make it suitable for the synthesis of pesticides, herbicides, and other agricultural chemicals that help protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
4-Bromo-3-nitrobenzamide is used as a key intermediate in the synthesis of various organic compounds. Its presence in the molecular structure allows for the formation of new compounds with different functional groups and properties, expanding the range of possible applications in research and industry.
Used in Research Applications:
4-Bromo-3-nitrobenzamide is used as a research chemical to study its properties and potential applications. Its unique structure and reactivity make it an interesting subject for scientific investigations, leading to a better understanding of its behavior and potential uses in various fields.

Upstream product

• 623-00-7 4-bromobenzenecarbonitrile 
• 6319-40-0 4-bromo-3-nitrobenzoic acid 
• 335015-51-5 4-bromo-3-nitrobenzoyl chloride 

Downstream Products

• 160003-66-7 4-iodo-3-nitrobenzamide 
• 41263-65-4 4-amino-3-nitrobenzamide 
• 16611-58-8 4-anilino-3-nitro-benzoic acid amide 

Relevant articles and documents

Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease, characterized by irreversible cognitive impairment, memory loss and behavioral disturbances, ultimately leading to death. Glycogen synthase kinase 3β (GSK-3β) and dual-specificity tyrosine phosphorylation regulated kinase1A (DYRK1A) have gained a lot of attention for its role in tau pathology. To search for potential dual GSK-3β/DYRK1A inhibitors, we focused on harmine, a natural β-carboline alkaloid, which has been extensively studied for its various biological effects on the prevention of AD. In this study, a new series of harmine derivatives were designed, synthesized and evaluated as dual GSK-3β/DYRK1A inhibitors for their multiple biological activities. The in vitro results indicated that most of them displayed promising activity against GSK-3β and DYRK1A. Among them, compound ZDWX-25 showed potent inhibitory effects on GSK-3β and DYRK1A with IC50 values of 71 and 103 nM, respectively. Molecular modelling and kinetic studies verified that ZDWX-25 could interact with the ATP binding pocket of GSK-3β and DYRK1A. Western blot analysis revealed that ZDWX-25 inhibited hyperphosphorylation of tau protein in okadaic acid (OKA)-induced SH-SY5Y cells. In addition, ZDWX-25 showed good blood-brain barrier penetrability in vitro. More importantly, ZDWX-25 could ameliorate the impaired learning and memory in APP/PS1/Tau transgenic mice. These results indicated that the harmine-based compounds could be served as promising dual-targeted candidates for AD.

Beta-carboboline GSK3beta/DYRK1A dual inhibitor and preparation method thereof and application of beta-carboboline GSK3beta/DYRK1A dual inhibitor in resisting Alzheimer's disease

The invention discloses a beta-carboline GSK3beta/DYRK1A dual inhibitor as shown in a general formula I, a preparation method of the beta-carboline GSK3beta/DYRK1A dual inhibitor and application of the beta-carboline GSK3beta/DYRK1A dual inhibitor in resi

Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides

A fast and efficient nickel-catalysed iodination reaction of aryl and heteroaryl bromides has been developed. The transformation was found to be general for a wide range of substrates and was used for the synthesis of iodo-PK11195, an imaging agent of Alzheimer's disease and iniparib, a compound used in the treatment of breast cancer.